Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,177,992 papers from all fields of science
Search
Sign In
Create Free Account
INCB028050
Known as:
INCB 028050
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
baricitinib
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers
Jack G. Shi
,
Xuejun Chen
,
+6 authors
S. Yeleswaram
Journal of clinical pharmacology
2014
Corpus ID: 6585611
Baricitinib (also known as LY3009104 or INCB028050), a novel and potent small molecule inhibitor of Janus kinase family of…
Expand
2013
2013
LB0005 12-week results of a phase 2B dose-ranging study of LY3009104 (INCB028050), an oral JAK1/JAK2 inhibitor, in combination with traditional dmards in patients with rheumatoid arthritis
E. Keystone
,
P. Taylor
,
+6 authors
W. Macias
2013
Corpus ID: 71247902
Background LY3009104 (LY) is a novel, oral inhibitor of the JAK1/JAK2 signalling pathway known to be important in the…
Expand
2013
2013
Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds
K. Migita
,
Y. Izumi
,
+10 authors
S. Motokawa
Clinical and Experimental Immunology
2013
Corpus ID: 25158711
Janus kinase (JAK) inhibitors have been developed as anti‐inflammatory agents and have demonstrated clinical efficacy in…
Expand
Review
2013
Review
2013
SP0169 JAK inhibition in patients with rheumatoid arthritis
J. Kremer
2013
Corpus ID: 76182595
The Janus Kinase (JAK) group of tyrosine kinases are intracellular signaling molecules which become phosphorylated upon…
Expand
2012
2012
F1000Prime recommendation of A Randomized Dose-Ranging, Placebo-Controlled Study of INCB028050, a Selective JAK1 and JAK2 Inhibitor in Subjects with Active Rheumatoid Arthritis.
J. O’Shea
2012
Corpus ID: 204059957
Highly Cited
2010
Highly Cited
2010
Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050
J. Fridman
,
P. Scherle
,
+19 authors
K. Vaddi
Journal of Immunology
2010
Corpus ID: 23711286
Inhibiting signal transduction induced by inflammatory cytokines offers a new approach for the treatment of autoimmune diseases…
Expand
2010
2010
Selective Inhibition of JAK 1 and JAK 2 Is Efficacious in Rodent Models of Arthritis : Preclinical Characterization of INCB 028050
J. Fridman
,
P. Scherle
,
+19 authors
K. Vaddi
2010
Corpus ID: 2296506
2010
2010
Preclinical Characterization of INCB 028050 Efficacious in Rodent Models of Arthritis : Selective Inhibition of JAK 1 and JAK 2 Is
J. Fridman
,
P. Scherle
,
+19 authors
K. Vaddi
2010
Corpus ID: 18342762
Review
2010
Review
2010
Are Th17 Cells an Appropriate New Target in the Treatment of Rheumatoid Arthritis?
H. Kato
,
D. Fox
Clinical and Translational Science
2010
Corpus ID: 2058066
Th17 cells play crucial roles not only in host defense but also in many human autoimmune diseases and corresponding animal models…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE